AstraZeneca Plc (PK) (AZNCF) News

AZN new 52=week high

AZN new 52 high

AZN new 52 week high

AZN new 52 week high

imo. the whole world read my post and AZN jerked their "vaccine" off of the market....worldwide.


Let's go lawsuits..... * * ***...........let's go lawsuits clap clap clap clap clap!



AZN



IHuser

AZN new 52 week high

imo... dirty people play dirty little number tricks see link AZN

https://www.bitchute.com/video/RZXLkuLaJrnz/

IHuser

anyone here see where enzolytics announced yesterday that they have a cure called clone 3 that CURES hiv/aids.?

anyone here see where enzolytics announced yesterday that they have a cure called clone 3 that CURES hiv/aids.?

lots of Deaths and Fatalities reported This could drop like a rock today heavy float lots of bagholders

Preprint https://www.biorxiv.org/content/10.1101/2023.06.20.545315v1

Next into the clinic should be this https://aacrjournals.org/cancerres/article/83/8_Supplement/LB085/725614/Abstract-LB085-Antitumor-activity-of-AZD0754-a

Also, a trial testing an CLDN18.2-targted version with the same dnTGFbRII armour is planned.

The first TCR-T therapy https://clinicaltrials.gov/ct2/show/NCT05877599 that is armoured as well http://www.neogene.com/staging/wp-content/uploads/2022/04/Keystone-2022-TGFBR2-KO-TP53-R175H-TCR-poster-final-edit.pdf

They have been working on additional edits https://jitc.bmj.com/content/10/Suppl_2/A253

AstraZeneca PLC $AZN Total Debt (mrq) $32.47B

Any idea why the delay for Ultomiris?

The company has inked a non-exclusive licensing deal with Revvity to use its Pin-point base editing platform in the development of new cell therapy treatments for cancer and other immune-mediated diseases. Pin-point uses a novel three-part design with an RNA aptamer guide, a modified Cas9 enzyme and a deaminase enzyme.

The platform is highly efficient and precise, allowing for multiplex editing with >75% editing in each target base. Also, has a strong safety profile with negligible off-target edits and no translocations. In addition, has no impact on cell health and allows for one-step complex engineering, which is simultaneous multiple knock-ins and knockouts (at least seven).

https://twitter.com/Prof_Oak_/status/1646929438594957312

got the wrong stock..... wanted AEZS

"INSIDE PFIZER AND ASTRAZENECA'S UKRAINIAN BIOLAB!":
https://www.bitchute.com/video/3JJO7BdvsDPz/

New PCR Test warning...Sodium Azide..."REMEMBER THE PCR TESTS? WELL THE MSM HAVE CONFIRMED THAT THEY WERE LACED WITH POISONOUS CHEMICAL."

https://www.bitchute.com/video/0zl8fPbSao75/

"THIS IS ABSOLUTELY BRILLIANT… STICKERS OF THE VACCINE INJURED ARE PLACE ON THE BBC HEADQUARTERS, A..":

https://www.bitchute.com/video/f2Y40NiPS6Kq/

"GOVT SCANDALOUSLY MADE IT MANDATORY FOR CARE WORKERS TO BE VACCINATED OR SACKED - WITH NO RISK..."

https://www.bitchute.com/video/Jq0lLY1CXZhn/

$AZN has $31.27 Billion DEBT

$AZN Book Value only $11.35

55.20, the FDA authorized the AstraZeneca drug called Evusheld for adults and children 12 and older whose immune systems haven't responded adequately to COVID-19 vaccines or have a history of severe allergic reactions to the shots. Regulators said the required two antibody injections may be effective at preventing COVID-19 infections for six months.

https://www.clickorlando.com/business/2021/12/08/us-oks-new-covid-19-antibody-drug-for-high-risk-patients/

$AZN Pfizer And AstraZeneca Vaccines Were As Effective As Prior Infection, U.K. Study Finds

IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy

Well, well, well
https://m.republicworld.com/technology-news/social-media-news/facebook-suspends-russian-accounts-running-anti-vaccine-campaign-against-astrazeneca.html

. U.K. Health secretary warns daily COVID-19 cases could reach 100,000

. AstraZeneca COVID-19 vaccine is effective against variants identified in India

$AZN EU Ditches AstraZeneca Vaccine. It's Pivoting to Pfizer. --

SEEMS LOW VOLUME ><((((((º>

https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84980530/farxiga-approved-in-the-us-for-the-treatment-of-ch

FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease

Interesting graph on India.

$AZN https://www.fool.com/investing/2021/04/22/pfizer-and-biontech-vaccine-sales-jump-14-billion/

my aptmt is april 8

dont want the AZN jab---its reported Sweden knows something

“ Emergent’s plant implicated in vaccine mix-up had issues cited by FDA in 2020: AP” is this a joke?

still a problem---AZN vaccine has to be carefully used---and kept cool

Reviews leave tbd ^ ^ ^ ^ ________________________AZN

BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors

LAVAL, Quebec—March 24, 2021— BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors. Dr. Mezzanotte brings decades of vast development and commercial experience to the Board, including the development and approval of 30 products across multiple therapeutic areas.

“Bill is a biopharmaceutical veteran with a proven drug development track record, including the approval of several drugs within the respiratory field,” commented Dr. Francesco Bellini, Chairman of BELLUS Health. “We are pleased to welcome Bill to our Board of Directors, and we look forward to leveraging his extensive knowledge and guidance to help position BLU-5937 for clinical, regulatory and commercial success.”

Dr. Mezzanotte is currently the Head of Research and Development and Chief Medical Officer at CSL Behring, where he is responsible for developing and executing the Research & Development strategy and portfolio across four continents. Prior to CSL, he was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim. At Boehringer Ingelheim, he oversaw all Global Clinical Development, Medical Affairs, Marketing and Payer activities within the Respiratory portfolio, overseeing the launch of three respiratory products. Previously, Dr. Mezzanotte worked at AstraZeneca for over 15 years, assuming roles of increasing leadership and management responsibility in clinical research and development across multiple therapeutic areas. His last role there was Head of the Inflammation, Neuroscience and Respiratory Global Medicines Unit. Earlier in his career, Dr. Mezzanotte practiced Pulmonary and Critical Care Medicine and ran both a multispecialty sleep disorders center and a pulmonary diagnostics and interventional bronchoscopy laboratory. He received an undergraduate degree from Villanova University and obtained his MD at the University of Pennsylvania and MPH from Johns Hopkins University. Dr. Mezzanotte is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine.

“I am excited to join BELLUS’ Board and contribute to the development of the Company’s promising lead candidate, BLU-5937,” said Dr. Mezzanotte. “Patients with refractory chronic cough have no FDA-approved treatments to help alleviate their symptoms. As a highly selective and differentiated P2X3 antagonist, BLU-5937 has the potential to offer meaningful improvement for these patients. I look forward to working with the BELLUS management team and other members of the Board to potentially bring this exciting therapy to the millions of patients that suffer from refractory chronic cough, as well as other hypersensitization-related disorders.”

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of refractory chronic cough and chronic pruritus associated with atopic dermatitis.

Refractory chronic cough is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from refractory chronic cough. Refractory chronic cough is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for refractory chronic cough and current treatment options are limited.

$AZN- true bozos from top to bottom https://www.cnbc.com/2021/03/11/denmark-suspends-use-of-astrazeneca-vaccine-over-reports-of-blood-clots.html

. AstraZeneca’s COVID-19 shot is said to work against Brazil variant: Reuters

AstraZeneca’s COVID-19 shots reach Ghana as UN-backed COVAX initiates deliveries

https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84421958/astrazeneca-s-covid-19-shots-reach-ghana-as-un-ba

WHO approves AstraZeneca/Oxford COVID-19 vaccine for emergency use

https://www.reuters.com/article/us-health-coronavirus-who-astrazeneca-idUSKBN2AF1KC

AstraZeneca Wins WHO Emergency Listing For COVID-19 Vaccine; Street Sees 31% Upside
https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84342162/astrazeneca-wins-who-emergency-listing-for-covid-1

Serum Institute expects WHO emergency approval for AstraZeneca Covid-19 vaccine Novavax soon

https://www.deccanherald.com/national/serum-institute-expects-who-emergency-approval-for-astrazeneca-covid-19-vaccine-novavax-soon-938986.html

AstraZeneca has applied for authorization for its Covid-19 vaccine in Europe and the EU pharmaceutical regulator said Tuesday it could give the go-ahead as early as Jan. 29. That´s when the European Medicines Agency´s scientific committee will meet to review analysis of the vaccine´s trial data and, if it recommends authorization, the European Commission could formally authorize AstraZeneca´s vaccine within a few days. If AstraZeneca´s Covid-19 vaccine, which was developed with Oxford University, were authorized for emergency use, it would add at least 300 million doses to the continent´s attempts to limit its deadly winter surge in Covid-19 infections. The EU has preordered 300 million doses with an option for another 100 million, and AstraZeneca has said it will manufacture up to three billion doses of its vaccine this year, which will be crucial in the effort to get doses administered in poorer countries.

FARXIGA Granted Priority Review in the US for the Treatment of Patients With Chronic Kidney Disease

https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84033951/farxiga-granted-priority-review-in-the-us-for-the

$AZN https://www.calcalistech.com/ctech/articles/0,7340,L-3884172,00.html

MHRA approves use of AZN/Oxford vaccine for use in U.K.